PL374077A1 - Zastosowanie antagonistów receptora 5-HT2 do leczenia zaburzeń snu - Google Patents

Zastosowanie antagonistów receptora 5-HT2 do leczenia zaburzeń snu

Info

Publication number: PL374077A1
Authority: PL; Poland
Prior art keywords: treatment; receptor antagonists; sleep disorders; sleep; disorders
Prior art date: 2002-10-04

Application number

PL03374077A

Other languages

English (en)

Inventor

Gerd Bartoszyk

Amsterdam Christoph Van

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-04

Filing date

2003-09-03

Publication date

2005-09-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32010223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL374077(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-03 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2005-09-19 Publication of PL374077A1 publication Critical patent/PL374077A1/pl

Links

102000056834 5-HT2 Serotonin Receptors Human genes 0.000 title 1
108091005479 5-HT2 receptors Proteins 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
208000019116 sleep disease Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Psychology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Indole Compounds (AREA)

PL03374077A 2002-10-04 2003-09-03 Zastosowanie antagonistów receptora 5-HT2 do leczenia zaburzeń snu PL374077A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10246357A DE10246357A1 (de)	2002-10-04	2002-10-04	Verwendung von 5-HT2Rezeptorantagonisten

Publications (1)

Publication Number	Publication Date
PL374077A1 true PL374077A1 (pl)	2005-09-19

Family

ID=32010223

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03374077A PL374077A1 (pl)	2002-10-04	2003-09-03	Zastosowanie antagonistów receptora 5-HT2 do leczenia zaburzeń snu

Country Status (18)

Country	Link
US (1)	US20060040951A1 (pl)
EP (1)	EP1545531A1 (pl)
JP (1)	JP2006503870A (pl)
KR (1)	KR20050054996A (pl)
CN (1)	CN1688309A (pl)
AR (1)	AR041476A1 (pl)
AU (1)	AU2003283237A1 (pl)
BR (1)	BR0314945A (pl)
CA (1)	CA2501082A1 (pl)
DE (1)	DE10246357A1 (pl)
MX (1)	MXPA05003437A (pl)
PE (1)	PE20040569A1 (pl)
PL (1)	PL374077A1 (pl)
RU (1)	RU2005113712A (pl)
TW (1)	TW200410691A (pl)
UA (1)	UA79993C2 (pl)
WO (1)	WO2004032932A1 (pl)
ZA (1)	ZA200503520B (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102004047517A1 (de) *	2004-09-28	2006-03-30	Merck Patent Gmbh	Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3865939A (en) *	1973-02-23	1975-02-11	Procter & Gamble	Edible oils having hypocholesterolemic properties
DE3119383A1 (de) *	1981-05-15	1982-12-02	Basf Ag, 6700 Ludwigshafen	Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinodpraeparaten
US5244887A (en) *	1992-02-14	1993-09-14	Straub Carl D	Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof
ATE246880T1 (de) *	1999-02-03	2003-08-15	Forbes Medi Tech Inc	Verfahren zur herstellung von phytosterol- oder phytostanol-mikropartikeln
DE19934433A1 (de) *	1999-07-22	2001-01-25	Merck Patent Gmbh	N-(Indolcarbonyl-)piperazinderivate
US6391370B1 (en) *	1999-11-12	2002-05-21	Kraft Foods, Inc.	Micromilling plant sterols and emulsifiers
US6576285B1 (en) *	2000-11-14	2003-06-10	Sunpure Ltd.	Cholesterol lowering beverage
DE10102944A1 (de) *	2001-01-23	2002-07-25	Merck Patent Gmbh	Verfahren zur Herstellung von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon und dessen Salzen
DE10157673A1 (de) *	2001-11-24	2003-06-05	Merck Patent Gmbh	Verwendung von N-(Indolcarbonyl-)piperazinderivaten

2002
- 2002-10-04 DE DE10246357A patent/DE10246357A1/de not_active Withdrawn
2003
- 2003-03-09 UA UAA200504236A patent/UA79993C2/uk unknown
- 2003-09-03 CA CA002501082A patent/CA2501082A1/en not_active Abandoned
- 2003-09-03 EP EP03775144A patent/EP1545531A1/de not_active Withdrawn
- 2003-09-03 CN CNA038235668A patent/CN1688309A/zh active Pending
- 2003-09-03 AU AU2003283237A patent/AU2003283237A1/en not_active Abandoned
- 2003-09-03 BR BR0314945-5A patent/BR0314945A/pt not_active IP Right Cessation
- 2003-09-03 US US10/530,051 patent/US20060040951A1/en not_active Abandoned
- 2003-09-03 RU RU2005113712/15A patent/RU2005113712A/ru not_active Application Discontinuation
- 2003-09-03 JP JP2004542340A patent/JP2006503870A/ja active Pending
- 2003-09-03 MX MXPA05003437A patent/MXPA05003437A/es not_active Application Discontinuation
- 2003-09-03 WO PCT/EP2003/009738 patent/WO2004032932A1/de not_active Ceased
- 2003-09-03 KR KR1020057005858A patent/KR20050054996A/ko not_active Withdrawn
- 2003-09-03 PL PL03374077A patent/PL374077A1/pl not_active Application Discontinuation
- 2003-09-30 TW TW092127070A patent/TW200410691A/zh unknown
- 2003-10-01 PE PE2003000995A patent/PE20040569A1/es not_active Application Discontinuation
- 2003-10-03 AR ARP030103600A patent/AR041476A1/es not_active Application Discontinuation
2005
- 2005-05-03 ZA ZA200503520A patent/ZA200503520B/en unknown

Also Published As

Publication number	Publication date
CN1688309A (zh)	2005-10-26
JP2006503870A (ja)	2006-02-02
DE10246357A1 (de)	2004-04-15
US20060040951A1 (en)	2006-02-23
EP1545531A1 (de)	2005-06-29
AU2003283237A1 (en)	2004-05-04
MXPA05003437A (es)	2005-07-05
KR20050054996A (ko)	2005-06-10
CA2501082A1 (en)	2004-04-22
AR041476A1 (es)	2005-05-18
RU2005113712A (ru)	2005-11-20
PE20040569A1 (es)	2004-08-30
UA79993C2 (en)	2007-08-10
WO2004032932A1 (de)	2004-04-22
TW200410691A (en)	2004-07-01
BR0314945A (pt)	2005-08-02
ZA200503520B (en)	2006-02-22

Legal Events

Date	Code	Title	Description
2012-10-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
HUE039348T2 (hu)	2018-12-28	A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra
PL376156A1 (pl)	2005-12-27	Antagoniści receptora PGD2 do leczenia chorób zapalnych
PL375053A1 (pl)	2005-11-14	Agoniści receptora sfingozyno-1-fosforanu w leczeniu zaburzeń demielinizacyjnych
AU2003249983A8 (en)	2004-02-09	Piperidines useful for the treatment of central nervous system disorders
PL372425A1 (pl)	2005-07-25	Pochodne III dihydrobenzodiazepin-2-onu
AU2003286567A8 (en)	2004-05-13	Methods for the treatment of skin disorders
AU2003285091A8 (en)	2004-06-07	Interferon antagonists useful for the treatment of interferon related diseases
IL161041A0 (en)	2004-08-31	Mch antagonists for the treatment of obesity
PT1666462E (pt)	2009-05-07	Derivados de n-[1h-indol-5-il]-naftaleno-1-sulfonamida e compostos associados enquanto antagonistas do receptor 5- ht6 de serotonina para o tratamento de distúrbios do sistema nervoso central
IL183656A0 (en)	2007-09-20	Indenyl derivatives and use thereof for the treatment of neurological disorders
IL157145A0 (en)	2004-02-08	Use of dc23 antagonists for the treatment of neoplastic disorders
AU2003290059A8 (en)	2004-07-09	Use of cd137 antagonists for the treatment of tumors
IL164697A0 (en)	2005-12-18	N-acyl piperidine derivatives for use as melanocortin receptor ligands in the treatment of feeding disorders
PL369822A1 (pl)	2005-05-02	Zastosowanie antagonistów receptora endoteliny doterapii chorób nowotworowych
PL370746A1 (pl)	2005-05-30	Pochodne piperazyny do stosowania jako antagoniści receptora CCR-3 w leczeniu astmy
AU2003267088A8 (en)	2004-04-30	Chemokine receptor antagonists as therapeutic agents
AU2003279841A8 (en)	2004-05-04	Uses of human zven antagonists
AU2003236649A8 (en)	2003-12-02	Egf receptor antagonists in the treatment of gastric cancer
PL356721A1 (pl)	2004-06-28	Zastosowanie mirtazapiny do leczenia zaburzeń snu
IL190783A0 (en)	2008-11-03	Indole derivatives as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other cns disorders
HRP20041160A2 (en)	2005-08-31	Novel combination for the treatment of airway disorders
AU2003259759A1 (en)	2004-02-25	Gal3 receptor antagonists for the treatment of affective disorders
AU2003264297A1 (en)	2004-04-30	Use of vanilloid receptor antagonists for the treatment of pain
AU2003273856A8 (en)	2004-04-19	Vr1 antagonists for the treatment of urological disorders
AU2003245995A8 (en)	2004-01-19	Use of gaba-c receptor antagonists for the treatment of myopia